Exxon Mobil, Nippon Steel and Mitsui to Commercialise High Strength Pipeline Steel - News Item

May 1 2003
Analyze Your Metals | Request a Quote

Exxon Mobil Upstream Research, Nippon Steel Corp and Mitsui and Co have jointly developed a new steel which is 20-50% stronger than currently used pipeline steels. To this end, the three companies have signed a letter of intent to commercialise the alloy.

As part of the commercialisation agreement, it is possible Nippon Steel will have their pipe mill upgraded.

The alloy was first developed by Exxon Mobil, who then collaborated with Nippon Steel to make commercial production viable.

The new high strength pipe steel is suited to applications such as natural gas pipelines, which will allow them to be built over longer distances at lower cost. With natural gas usage growing, and resources being located remotely from usage centres, lower cost pipelines could help to make such ventures more economically viable.

 

Posted April 22nd, 2003

 

Tell Us What You Think

Do you have a review, update or anything you would like to add to this article?

Leave your feedback
(Logout)
Your comment type
Submit

Sponsored Content

Editorial Highlights

The Current State of the Global Semiconductor Market

The Current State of the Global Semiconductor Market

The global semiconductor market has entered an exciting period. Demand for chip technology is both driving the industry as well as hindering it, with current chip shortages predicted to last for some time. Current trends will likely shape the future of the industry, which is set to continue to show

How are Graphene Batteries Made?

How are Graphene Batteries Made?

The primary distinction between graphene-based batteries and solid-state batteries lies in the composition of either electrode. Although the cathode is commonly changed, carbon allotropes can also be employed in fabricating anodes.

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback